Business Wire

MENTIMETER

14.3.2023 14:02:41 CET | Business Wire | Press release

Share
Mentimeter Announces Expansion of New North American Headquarters in Toronto as Company Scales for Growth

Mentimeter, the leading audience engagement platform, today announced the expansion of its North American headquarters based in Toronto, Canada, with the appointment of Tobias Porseurd to the role of North American General Manager. The news comes on the heels of the company’s successful Series C funding round in 2022, which aimed to support its growing organizational adoption in North America. Mentimeter reported a 281% year-over-year increase in customers and an 85% increase in revenues from the North American region in 2022. Currently, 30% of Mentimeter’s global customers are based in the U.S. and Canada.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005002/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tobias Porseurd, North America General Manager at Mentimeter (Photo: Business Wire)

“Our substantial growth in North America signifies the staying power of Mentimeter as a post-pandemic workplace engagement tool that brings organizational value by powering better employee performance, productivity and informed decision-making,” said Johnny Warström, co-founder and CEO of Mentimeter. “We are thrilled that Tobias is leading our expansion efforts from Toronto as he brings proven success in scaling businesses that will allow our workforce to keep up with surging demand for our solution.”

To keep pace with rising demand, Mentimeter’s expansion is aimed at increasing headcount by 50%, led by Porseurd, who began his career at Mentimeter in May 2021 as the director of talent acquisition in Stockholm, Sweden. During that time, Porseurd was responsible for the strategic direction and management of the SaaS scale-up and ensuring Mentimeter continues to be a great place to work by helping attract employees to an inclusive, fun and collaborative environment. Through this role, Porseurd helped recruit over 100 employees in less than 12 months. Prior to joining Mentimeter, he was the co-founder and board member of Talent Eye, a talent recruitment company that provides solutions and interventions to employees. He has recently relocated to Toronto, Canada with his family.

“Mentimeter values creating meaningful connections with its customers, which begins with proximity,” said Porseurd. “As the North America General Manager, I intend to take a holistic approach to building and deepening North American customer relationships and empowering our client-base to create a positive, supportive and productive workforce. I’m also excited to expand our office by bringing in top talent in the area to provide our innovative offering across enterprises of all sizes as well as universities.”

About Mentimeter:

Mentimeter, a leading audience engagement platform, makes it easier to gather input and beautifully visualize it in real-time - transforming a passive audience into active contributors. Mentimeter is fundamentally changing the culture of presentations, lectures, and workshops in business and education from talking to listening. Whether on-site, remote, or hybrid, Mentimeter creates a unique, transparent, and engaging experience for everyone. Since launching in 2012, users have gathered opinions, questions, and thoughts through more than 35 million presentations utilizing the Mentimeter platform.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005002/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye